-
Sunday, 11/18/2018
Roberto Cabrera and Anna Motos presented the results of two studies at the latest Jornadas de formación Ciberes
The meeting was hold last 15-16 of november 2018 in Madrid and involved more than 100 national researchers, 20 oral presentations and 40 posters on respiratory diseases and lung cancer
Roberto Cabrera, postodoctoral Ciberes researcher presented an oral presentation entitled: “Molecular characterization of antibiotic resistance mechanisms in methicilin- resistant Staphylococcus aureus from ICU endotracheal tubes”.
Anna Motos, Ciberes researcher and coordinator of animal Studies, presented a poste ron the study entitled “Is One Sample Enough? β-lactam Target Attainment and Penetration into Epithelial Lining Fluid based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model”.
-
Friday, 11/09/2018
IAMR achieved funding for two projects at the health national call 2018 (FIS)
The success warrants funding for the next three years in the laboratory and in the ventilador associated research lines
Dr. Antoni Torres and Dr. Laia Fernández Barat co-leaded the project entitled “Importance of Pseudomonas aeruginosa biofilms in exacerbations in patients with bronchiectasis with and without Chronic Obstructive pulmonary disease ”. This project achieved 196.000 euros.
Dr. Miquel Ferrer leaded the project entitled “Driving Pressure and Inflammation in Acute Respiratory Distress Syndrome”. This Project achieved 147.000 euros and will be the end of residency project of Enric Barbeta. -
Wednesday, 10/31/2018
IAMR succeeds in the latest La Marató TV3 grants on infectious diseases
An individual Project in collaboration with Prof. Marcos Restrepo from San Antonio, Texas, USA and leaded by Prof. Antoni Torres achieves 200.000 euros
The project granted is entitled “Pulmonary and cardiac injury caused by severe pneumococcal pneumonia: appraisal of the benefits of corticosteroids and macrolides” and will be the continuation of a national competitive project on our pig animal model of severe pneumonia due to Streptococcus pneumoniae. Both projects leaded by Prof. Antoni Torres, the IAMR group leader.
-
Friday, 10/26/2018
Nil Vázquez joins the Research Group
He will participate in the laboratory research line
During his collaboration Nil Vázquez will focus on experimental studies concerning the biofilm production by Pseudomonas aeruginosa in COPD and Bronchiectasis.
4th year student from the Barcelona University (UB) on biomedical science. He joined the research group in November 2017 to perform a research collaboration taking part on the biofilm research line leaded by the coordinator of the research laboratory, Dr. Laia Fernández-Barat. -
Wednesday, 07/11/2018
Antonella Ielpo succesfully finishes her research stay in the IAMR group
During her fellowship she focused on studies concerning bronchiectasis and COPD
The latest incorporation at the research group is Antonella Ielpo, who holds a Degree in Medicine at the University of Chieti (Italy) in the year 2013. Currently, she is resident in Respiratory Diseases at the University of Parma. In our group, she worked during four months in the research concerning Bronchiectasis and COPD exacerbations.
-
Friday, 04/27/2018
2 IAMR Group Research Projects have been awarded by SEPAR in the 2017 Call for Grant Applications
The SEPAR 2017 Grants of Fundació Respira (Spanish Lung Foundation) will invest around 600.000 euros in research
The IAMR research team has been successful in the 2017 call for the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) - Fundació Respira grants (http://www.separ.es). Miquel Ferrer and Enric Barbeta obtained funding to carry out their research projects in the field of respiratory diseases.
Dr. Miquel Ferrer obtained a SEPAR 2017 grant for his project Reducing the duration of antibiotic treatment of community-acquired pneumonia with high risk class and initially appropriate response. A randomised clinical trial. The aims for this trial are: 1) To assess the efficacy of 5-day antibiotic treatment compared to the usual duration of more than 7 days, in a non-inferiority design, in terms of “mortality, hospital readmission or reinitiating of antibiotic treatment at 30 days”, in a cohort of patients with community-acquired pneumonia with a PSI risk class IV-V who present an initially adequate response to treatment (clinical stability within the first 4 days of treatment alter admission); 2) To assess the efficacy of 5-day antibiotic treatment compared to the usual duration of more than 7 days on hospital lenght of stay and antibiotic-free days at 30 days and; 3) To investigate the occurrence of adverse events related to the use of study antibiotics
Enric Barbeta obtained a SEPAR 2017 grant for his project Driving Pressure and Inflammatation in Acute Respiratory Distress Syndrome. The aim of this project is to analyze the association between driving pressure and pulmonary and systemic inflammation as well as the severity of multiorgan failure in patients with ARDS undergoing invasive mechanical ventilation.
SEPAR-Fundació Respira awards a number of grants each year with the aim of encouraging research in the field of respiratory disease. -
Tuesday, 12/12/2017
A new combination of antibiotics allows treating 60% of hospital-acquired pneumonia
A study published in the journal The Lancet Infectious Diseases shows the ability of a new antibiotic (ceftazimida-avibactam) to treat hospital-acquired pneumonia, including ventilation-associated pneumonia. It has similar efficacy to one of the most used type of antibiotics in the treatment of this infection, carbapenems, but has the advantage of overcoming problems derived from its administration, such as the resistance of certain bacteria. Dr. Antoni Torres, Head of the Respiratory Intensive Surveillance Unit (UVIR) of the Hospital Clínic and head of the IDIBAPS team on Applied research in infectious respiratory diseases, is the principal investigator of the study and first author of the article.
-
Wednesday, 11/08/2017
A blood test allows the identification of patients with pneumonia with a higher associated mortality
The work has been published by the journal EBioMedicine.
A multidisciplinary team of researchers, led by the Hospital Clínic de Barcelona-IDIBAPS, the La Fe Hospital in Valencia and the Valladolid University Clinic Hospital, has identified an immunological subtype of Pneumonia Acquired in the Community (CAP) that is associated to a greater mortality. It is a community pneumonia with low blood lymphocytes and has twice the risk of mortality. Patients with this subtype are easy to identify using a simple hemogram, the most common blood test available in all hospitals. The work has been published by the journal EBioMedicine.
-
Friday, 10/20/2017
CHEST 2017 Murray Kornfeld Memorial Founders lecture
Prof. Antoni Torres, research Group leader of Applied research in Respiratory diseases, has been recognized as recipient of the prestigious CHEST 2017 Murray Kornfeld Memorial Founders lecture. CHEST 2017 will be held in Toronto, Ontario, Canada, October 28-November 1, 2017. There, Prof. Torres will give a lecture entitled: “Barcelona Respiratory Research Group: Trying to Change Clinical Practice”, a summary of the most relevant research findings that have changed clinical practice worldwide. Prof. Torres will be recognized and given his award at his lecture on Wednesday, November 1 at 11:00 am at the Convention Center.
-
Sunday, 10/15/2017
Denise Battaglini joins the Research Team
During her fellowship she will focus on experimental studies concerning animal models of pulmonary infection
Doctor from the University of Genova (IT) and graduated in Medicine at the University of Genova (IT) in 2013 with Laude. She is resident physician in Anesthesiology and Intensive Care in Genoa University. She joined the research group in October 2017 to perform a Research Fellowship for one year taking part of the Animal Model line.
